Trial Profile
A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SAFE
- Sponsors Biogen Idec
- 29 Jan 2008 Status changed from recruiting to completed according to ClinicalTrials.gov
- 15 Jul 2007 New trial record.